Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is well-positioned for success due to their strong pipeline and positive Phase 2b data for their lead drug candidate EVO756 in chronic spontaneous urticaria (CSU). With promising results and data supported by their successful enrollment in their Phase 2b trial, Evommune has a strong chance of entering the Phase 3 trial with a differentiated oral profile in a competitive market. Additionally, the company showed improved financials with lower expenses and a significant increase in cash reserves, providing strong backing for their continued development. However, risks include competition from established biologics and other companies with similar mast cell-directed therapies, as well as potential safety concerns as the product advances through clinical trials. Overall, with a conservative discounted cash flow valuation method, Evommune has a strong 30% probability of approval and a 12-month price objective of $50 per share, making it a Buy for potential investors.

Bears say

Evommune is a clinical-stage biotechnology company with a focus on creating new therapies for chronic inflammatory diseases like CSU, AD, and UC. However, the company's early data in these areas has not been able to demonstrate compelling efficacy over key competitors and there is potential for unexpected toxicity in longer studies, which could lead to downside revisions. Additionally, the company's focus on progressing a single drug to market and its limited resources may hinder its ability to sustain and expand its pipeline, making it less attractive to investors.

Evommune Inc (EVMN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 8 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.